Who We Are
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning treatment for immune-excluded tumors. Our deliberate drug development strategy is based in the pathology of these tumors. We are crafting sophisticated, science-driven immune therapies to target key mechanisms of immune resistance.
Our approach could unlock the full potential of immunotherapy for the millions of patients who present with immune-excluded tumors.
Imagine treatment efficacy in immune-excluded tumors
Dr. Michael Curran founded ImmunoGenesis in 2019 around a unique cytotoxic immune checkpoint inhibitor (ICI): IMGS-001, designed to destroy barriers blocking T cells, provide best-in-class PD-1 blockade, and activate T cells once they are at the tumor and ready to attack.
Learn more about Dr. Curran’s visionDeveloping revolutionary ideas in medicine requires the collaboration of experts. ImmunoGenesis has built a strong team of employees and advisors to make the vision of Dr. Curran a reality.
Meet the team
Millions without effective treatments
First-generation PD-1 inhibitors have represented a major advance in certain immune-inflamed tumors, characterized by a robust T-cell response gathered at the tumor and ready to attack. In these tumors, first-generation PD-1 inhibitors have driven robust and durable responses.
|
Unmet needUnfortunately, the immune-excluded subtype, which has activated T cells that are locked out of the tumor bed, is the largest immune phenotype in tumors such as colorectal, ovarian, and non–small cell lung cancer. The immune-excluded subtype has been associated with resistance to PD-(L)1 blockade because these T cells can’t get to the target tumor. Across all tumors, the response rate to PD-1 blockade is only 15%. |
Market Position
Rethinking immunotherapy and well-positioned for growth
We are positioned to thrive. We have a secure manufacturability profile, a highly defensible IP position, and multiple products currently in clinical trials. Cautious estimates hint at a market greater than $70 billion.
And we’re just getting started. Are you ready to help us redefine the immune-excluded tumor treatment landscape?